乾癬性関節炎における滑膜炎の対するSecukinumab の超音波パワードップラーを用いた評価: 第３相 ULTIMAT試験の12-週結果
doi: 10.1093/rheumatology/keab628
D'Agostino, et al. aimed to evaluate whether treatment with secukinumab inhibits synovitis in patients with active PsA, as measured by PDUS. They found that secukinumab rapidly and significantly decreased synovitis, indicating a direct effect of IL-17 inhibition on the synovium in patients with PsA.